Indaptus Therapeutics, Inc. (NASDAQ:INDP) Sees Large Drop in Short Interest

Indaptus Therapeutics, Inc. (NASDAQ:INDP) saw a significant decline in short interest in the month of January. As of January 15th, there was short interest totaling 68,026 shares, a decline of 73.9% from the December 31st total of 260,406 shares. Currently, 4.0% of the shares of the company are short sold. Based on an average daily trading volume, of 141,361 shares, the days-to-cover ratio is presently 0.5 days. Based on an average daily trading volume, of 141,361 shares, the days-to-cover ratio is presently 0.5 days. Currently, 4.0% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Indaptus Therapeutics in a research note on Thursday, January 22nd. Wall Street Zen cut Indaptus Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 6th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Indaptus Therapeutics Stock Performance

Shares of INDP traded up $0.01 during mid-day trading on Friday, reaching $2.20. The stock had a trading volume of 23,851 shares, compared to its average volume of 108,270. The business has a fifty day moving average of $2.54 and a 200 day moving average of $4.24. The firm has a market cap of $4.93 million, a price-to-earnings ratio of -0.07 and a beta of 0.98. Indaptus Therapeutics has a 12 month low of $1.65 and a 12 month high of $47.60.

Indaptus Therapeutics (NASDAQ:INDP) last released its earnings results on Wednesday, November 12th. The company reported ($2.98) earnings per share for the quarter, beating analysts’ consensus estimates of ($4.17) by $1.19. On average, research analysts forecast that Indaptus Therapeutics will post -1.79 EPS for the current fiscal year.

Institutional Trading of Indaptus Therapeutics

A hedge fund recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC purchased a new position in Indaptus Therapeutics, Inc. (NASDAQ:INDP) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 1.72% of Indaptus Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 7.06% of the company’s stock.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.